Does Ozempic Cause Hair Loss? What the Research Says (2026)
Yes, GLP-1 medications like Ozempic can cause temporary hair shedding in some patients. The condition is called telogen effluvium and is triggered by rapid weight loss — not the drug itself. Clinical trials report 3-5% incidence, though real-world rates may be higher. The good news: it is almost always temporary and largely preventable.
Ozempic Hair Loss at a Glance
A 2025 medRxiv study analyzing over 500,000 patients found women using semaglutide had a 2.08x higher risk of hair loss compared to those on bupropion-naltrexone. The STEP 1 Wegovy trial reported 3% alopecia in the semaglutide group versus 1% placebo, rising to 5.3% among those who lost more than 20% of body weight. FDA adverse event data shows a reporting odds ratio of 2.46 for semaglutide and alopecia.
Does Ozempic Actually Cause Hair Loss?
The short answer is yes — but with an important nuance. Ozempic (semaglutide) does not directly damage hair follicles or trigger hair loss through its pharmacological mechanism. Instead, the rapid weight loss and significant caloric deficit that GLP-1 medications produce creates a form of metabolic stress that pushes hair follicles from the growth phase (anagen) into the resting and shedding phase (telogen). This is called telogen effluvium.
The same pattern of hair shedding occurs after bariatric surgery, crash diets, childbirth, major illness, or any significant physiological stress. A 2025 systematic review published in the Journal of the European Academy of Dermatology and Venereology confirmed that the “best described mechanism for hair loss related to these novel weight loss agents is a telogen effluvium mechanism.”
Key Distinction: Rapid Weight Loss, Not the Drug
Cleveland Clinic, Mayo Clinic, and leading dermatologists confirm that hair shedding on GLP-1 medications is a consequence of rapid weight loss itself — not a direct pharmacological side effect of semaglutide or tirzepatide. Any method of losing a large amount of weight quickly carries the same risk. However, because GLP-1 drugs produce faster weight loss than diet alone, they are more likely to trigger this response.
How Common Is GLP-1 Hair Loss?
Hair loss rates vary significantly depending on the study, the medication, the dose, and the amount of weight lost. Here is what the clinical evidence shows.
Semaglutide (Wegovy)
3% (drug) vs. 1% (placebo)Source: STEP 1 Trial
The pivotal Wegovy trial reported alopecia in 3% of semaglutide 2.4mg users versus 1% with placebo. Among patients who lost more than 20% of their body weight, the rate rose to 5.3%. An FDA adverse event analysis found a reporting odds ratio (ROR) of 2.46 for semaglutide and alopecia — meaning reports are 2.46 times more likely than expected.
Tirzepatide (Zepbound)
Up to 5.7% at highest doseSource: SURMOUNT-1 Trial
The SURMOUNT-1 trial for tirzepatide 15mg reported alopecia in approximately 5.7% of participants. A pharmacovigilance analysis found a reporting odds ratio of 1.73 for tirzepatide and alopecia. The higher incidence may correlate with tirzepatide's greater average weight loss (~22.5% vs. ~15% for semaglutide).
Real-World Data (2025-2026)
Likely higher than trial dataSource: Retrospective Cohort Studies
A 2025 medRxiv study of over 500,000 patients found women using semaglutide had a 2.08x adjusted hazard ratio for hair loss compared to bupropion-naltrexone users. Dermatologists report at the 2025-2026 AAD meetings that real-world rates appear higher than clinical trial data, likely due to aggressive titration schedules and inadequate nutritional guidance in many telehealth programs.
Why Hair Loss Happens on GLP-1 Medications
Understanding the mechanism helps explain why hair loss occurs and why it is temporary. The human hair growth cycle has three phases, and rapid weight loss disrupts the normal balance.
Anagen (Growth Phase)
Normally, 85-90% of your hair is in the active growth phase, which lasts 2-7 years. Hair follicles are actively dividing and producing new hair. This phase requires significant energy and nutrients, especially protein, iron, and zinc.
Catagen (Transition)
A brief 2-3 week transition where follicles stop growing. Under normal conditions, only about 1% of hair is in this phase at any time. When your body is under metabolic stress, it prematurely pushes more follicles into this transition.
Telogen (Shedding Phase)
Normally 10-15% of hair is resting and ready to shed. In telogen effluvium, up to 30% or more of follicles shift into this phase simultaneously. This causes noticeable thinning and excess shedding 2-4 months after the triggering event — which is why hair loss often appears months into GLP-1 treatment.
Contributing Factors
Caloric Deficit and Metabolic Stress
GLP-1 medications dramatically reduce appetite, often leading to caloric intake of 800 to 1,200 calories per day. Your body interprets this severe energy restriction as a survival threat and diverts resources away from non-essential functions — including hair growth. The more aggressive the caloric deficit, the greater the shedding risk.
Protein Deficiency
Hair is made of keratin, a protein. When dietary protein is insufficient — common when appetite is dramatically suppressed — the body prioritizes protein for vital organs over hair follicles. Many GLP-1 patients consume less than 50 grams of protein daily, well below the 0.7 to 1 gram per pound recommended during active weight loss.
Iron and Zinc Deficiency
Reduced food intake often leads to micronutrient deficiencies. Iron deficiency (with or without anemia) is one of the most common causes of telogen effluvium independent of GLP-1 use. Zinc deficiency impairs keratin synthesis and slows follicle recovery. Both are frequently low in patients eating significantly less food.
Rapid Rate of Weight Loss
Losing more than 1 to 2 pounds per week significantly increases telogen effluvium risk. Some GLP-1 patients lose 1% or more of body weight per week, especially at higher doses. The STEP 1 trial data showed hair loss rates of 5.3% among those losing more than 20% of body weight, versus 2.5% for those losing less — a clear dose-response relationship with weight loss magnitude.
How to Prevent Hair Loss on GLP-1 Medications
Prevention is far more effective than treatment. These evidence-based strategies can significantly reduce or eliminate hair shedding while you are still losing weight.
Prioritize Protein (0.7-1g per lb)
This is the single most important prevention strategy. Aim for 0.7 to 1 gram of protein per pound of body weight daily. For a 180-pound person, that means 126 to 180 grams of protein per day. Prioritize lean meats, fish, eggs, Greek yogurt, cottage cheese, and protein shakes. Since GLP-1 medications suppress appetite, many patients find it easier to hit protein goals by eating protein first at every meal and using a whey or collagen protein supplement.
Supplement Key Nutrients
Ask your doctor to check iron (ferritin), zinc, vitamin D, and B12 levels. Ferritin should ideally be above 40 ng/mL for optimal hair growth. Consider supplementing with biotin (2,500-5,000 mcg daily), a hair-specific multivitamin containing iron, zinc, and selenium, and collagen peptides (10-15g daily). Vitamin D deficiency — common in the general population — also contributes to hair shedding and should be corrected.
Slower Dose Escalation
Work with your prescriber to follow a gradual titration schedule. Instead of jumping to the maximum dose, stay at each dose level for 6 to 8 weeks rather than the minimum 4. Dermatologists presenting at the 2025-2026 AAD meetings specifically identified aggressive titration as a key driver of higher real-world hair loss rates compared to clinical trials. Losing 1 to 2 pounds per week — not 3 to 4 — dramatically reduces telogen effluvium risk.
Eat Enough Calories
Even though GLP-1 medications suppress appetite, try not to drop below 1,200 calories per day (women) or 1,500 calories (men). Extremely low calorie intake accelerates nutrient deficiencies and metabolic stress. Tracking food intake — even loosely — helps ensure you are eating enough to support hair health while still losing weight. Focus on nutrient-dense whole foods rather than empty calories.
Stay Hydrated
Dehydration — common on GLP-1 medications due to reduced food and fluid intake — impairs nutrient delivery to hair follicles and makes thinning appear worse. Aim for at least 64 ounces (2 liters) of water daily. Dehydration also exacerbates the GI side effects of GLP-1 drugs, creating a cycle of nausea and further reduced intake that compounds hair health issues.
Gentle Hair Care
While you cannot stop telogen effluvium with hair care alone, you can minimize breakage and visible thinning. Avoid tight hairstyles, excessive heat styling, and harsh chemical treatments. Use a wide-tooth comb on wet hair, switch to a sulfate-free shampoo, and consider minoxidil 5% (Rogaine) if shedding is significant — dermatologists report it can help accelerate the recovery phase even in telogen effluvium.
When Does the Hair Loss Stop?
Telogen effluvium is a self-limiting condition. Here is the typical timeline based on clinical evidence and dermatologist guidance.
Months 2-4: Shedding Begins
Hair loss typically becomes noticeable 2 to 4 months after starting a GLP-1 medication (or after significant weight loss begins). This delay occurs because it takes several weeks for follicles pushed into telogen to actually release the hair shaft. You may notice more hair in the shower drain, on your pillow, or in your brush.
Months 4-6: Peak and Plateau
Shedding typically peaks around 3 to 4 months after onset and begins to slow as your body adapts to the new weight and metabolic state. If you have corrected nutritional deficiencies and stabilized your caloric intake, this phase often resolves faster. Some patients experience a shorter shedding period of just 6 to 8 weeks.
Months 6-12: Regrowth
Once shedding stops, follicles re-enter the anagen (growth) phase and new hair begins to grow. Full regrowth typically takes 6 to 12 months from when shedding stops. The new hair may initially appear finer or shorter, but it will eventually return to normal thickness. Nearly all patients with telogen effluvium experience complete regrowth.
When to See a Doctor
While most GLP-1-related hair shedding is benign telogen effluvium that resolves on its own, there are situations where you should consult a dermatologist or your prescribing physician.
Hair loss has not slowed after 6 months
Telogen effluvium typically resolves within 3 to 6 months. If shedding continues beyond 6 months, there may be an ongoing nutritional deficiency, thyroid disorder, or another underlying cause that needs evaluation.
You notice bald patches or patchy hair loss
Telogen effluvium causes diffuse, even thinning — not bald patches. Patchy hair loss could indicate alopecia areata (an autoimmune condition), fungal infection, or another diagnosis that requires different treatment.
Significant thinning with visible scalp
While some thinning is expected, severe thinning with visible scalp through the hair warrants a dermatology evaluation. A trichoscopy exam can determine the exact cause and rule out other conditions.
Hair loss accompanied by other symptoms
If hair loss is accompanied by fatigue, cold intolerance, weight gain despite medication, or brittle nails, this may indicate thyroid dysfunction or severe iron deficiency anemia that needs blood work and treatment.
You are experiencing significant emotional distress
Hair loss can significantly impact self-esteem and mental health. If shedding is causing anxiety or depression, a dermatologist can discuss treatment options including topical minoxidil, PRP therapy, or in some cases low-level laser therapy (LLLT) to accelerate regrowth.
Frequently Asked Questions
Does Ozempic directly cause hair loss?
Ozempic (semaglutide) does not directly cause hair loss through a pharmacological mechanism. The hair shedding associated with GLP-1 medications is telogen effluvium — a temporary condition triggered by the rapid weight loss and caloric deficit these drugs produce. The same type of hair loss occurs after bariatric surgery, crash diets, or any significant metabolic stress. However, a 2025 study of over 500,000 patients found women on semaglutide had a 2.08x higher risk of hair loss compared to those on bupropion-naltrexone, confirming the association is real even if the mechanism is indirect.
How common is hair loss on Ozempic or Wegovy?
In clinical trials, approximately 3 to 5.3% of semaglutide users reported alopecia. The STEP 1 trial for Wegovy found 3% alopecia in the semaglutide group versus 1% in the placebo group. Among patients who lost more than 20% of their body weight, the rate rose to 5.3%. Real-world data from FDA adverse event reports and retrospective cohort studies suggest the true prevalence may be higher, particularly in women and those on aggressive titration schedules.
Will my hair grow back after Ozempic hair loss?
Yes, in the vast majority of cases. Telogen effluvium is a temporary, self-limiting condition. Once your body adapts to its new weight, nutritional intake stabilizes, and the metabolic stress resolves, hair follicles re-enter the growth (anagen) phase. Most patients see shedding slow within 3 to 6 months and full regrowth within 6 to 12 months. Ensuring adequate protein, iron, zinc, and biotin intake can speed recovery.
Can I prevent hair loss while taking Ozempic?
You can significantly reduce the risk by consuming 0.7 to 1 gram of protein per pound of body weight daily, supplementing with iron (if deficient), zinc, biotin, and vitamin D, following a slower dose escalation schedule to avoid rapid weight loss of more than 1 to 2 pounds per week, staying well-hydrated, and avoiding very low calorie intake. Working with your prescriber on a gradual titration schedule is one of the most effective strategies.
Does tirzepatide (Mounjaro/Zepbound) also cause hair loss?
Yes, tirzepatide has also been associated with hair loss in clinical trials and real-world reports. A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found a significant association between tirzepatide and alopecia with a reporting odds ratio of 1.73. The SURMOUNT-1 trial for Zepbound reported alopecia in approximately 5.7% of participants at the highest dose. As with semaglutide, the hair loss is believed to result from rapid weight loss and metabolic changes rather than a direct drug effect.
Sources & References
- Cleveland Clinic — Does Ozempic Cause Hair Loss? What We Know
- medRxiv (2025) — Risk of Hair Loss with Semaglutide for Weight Loss (500,000+ Patient Study)
- PMC — Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- PMC — Hair Loss Associated With GLP-1 Receptor Agonist Use: A Systematic Review
- JEADV (Wiley, 2025) — Exploring the Hair Loss Risk in GLP-1 Agonists: Emerging Concerns
- GoodRx — Does Ozempic Cause Hair Loss? Here’s What Studies Say
- CNN Health (2025) — Why Some People Lose Their Hair When They’re on GLP-1s
- Drugs.com — Do Ozempic, Wegovy, Mounjaro & Zepbound Cause Hair Loss?